Studies of human mutations have paved the way toward understanding elevated plasma cholesterol levels, both by exposing the mechanisms of lipid transport and by focusing hypotheses for further studies (1, 2). In this issue, Pullinger et al. (3) studied a kindred with hypercholesterolemia and identified a mutation in \textit{CYP7A1}, which encodes cholesterol 7\(\alpha\)-hydroxylase, the first and rate-limiting step in the classical bile acid synthetic pathway (4). As has been the case before, this new mutation has simultaneously shed light on mechanisms of lipid metabolism and raised a welter of issues for future investigation.

The study by Pullinger et al. (3) must have been supremely gratifying for the authors: They started with an imaginative hypothesis about hypercholesterolemia — one rooted in simple clinical findings — and, after some serious screening efforts, hit pay dirt. They hypothesized that \textit{CYP7A1} deficiency would reduce the conversion of cholesterol to bile acids, resulting in elevated liver cholesterol levels, downregulated LDL receptors, and hypercholesterolemia. They further hypothesized that the increased hepatic cholesterol levels would render these patients resistant to the hypocholesterolemic effect of statins and that \textit{CYP7A1} deficiency would cause premature gallstone disease, a result of reduced bile acid secretion rates. By screening appropriate patients from their lipid clinic, they identified two brothers, both with premature gallstone disease and statin-resistant hypercholesterolemia, who were homozygous for a frameshift mutation in \textit{CYP7A1} that abolished enzyme activity. A third homozygote also had hypercholesterolemia, and six heterozygotes had higher cholesterol levels than unaffected family members, leading the authors to conclude that \textit{CYP7A1} deficiency in humans causes hypercholesterolemia. This conclusion is consistent with population studies that have shown an association between plasma cholesterol levels and polymorphisms at the \textit{CYP7A1} locus (5, 6).

While the guiding hypothesis of Pullinger et al. (3) is attractive, we believe that a cautionary note should be sounded about the hyperlipidemic phenotype. Because the authors identified a hyperlipidemic kindred within a tertiary care lipid clinic, the possibil-

---

**Figure 1**

(a) The classical pathway for bile acid synthesis begins with \textit{CYP7A1}, which converts cholesterol into 7\(\alpha\)-hydroxycholesterol. This pathway mainly produces cholic acid in humans. (b) Alternate pathways for bile acid synthesis. Cholesterol is first converted into oxysterols by one of three different enzymes: sterol 27-hydroxylase (\textit{CYP27}), expressed in multiple tissues including liver; cholesterol 25-hydroxylase, present at low levels in multiple tissues including heart, lung, and kidney; and cholesterol 24-hydroxylase (\textit{CYP46}), expressed predominantly in the brain. Oxysterols are transported through the bloodstream to the liver, where they are 7\(\alpha\)-hydroxylated by \textit{CYP7B1}, the 25- and 27-hydroxysterol in the case of 25- and 27-hydroxycholesterol and by \textit{CYP39A1} in the case of 24-hydroxycholesterol. Alternate pathways preferentially produce chenodeoxycholic acid in humans.
ity of ascertainment bias must be considered, particularly since their kindred was not particularly large and since the conclusions were based on a limited number of lipid measurements. More kindreds with CYP7A1 mutations will be needed if the phenotype is to be defined conclusively.

Assuming that the hypercholesterolemic phenotype is upheld by future studies, it will be crucial to explore mechanisms. Their hypothesis holds that CYP7A1-deficient subjects have elevated liver cholesterol levels leading to reduced LDL receptor activity and retarded removal of LDL from the bloodstream. This hypothesis must be tested. The VLDL and LDL turnover rates in CYP7A1-deficient subjects should be measured and compared with those in both normal controls and subjects with the heterozygous form of familial hypercholesterolemia.

**CYP7A1 and triglycerides**

A surprising and unexplained finding in the current study was the observation that two of the three homozygotes were hypertriglyceridemic. For years, lipidologists have observed hypertriglyceridemia in patients on bile acid sequestrants, where bile acid synthesis rates are high (7, 8). It seems curious that low levels of bile acid synthesis, as in CYP7A1 deficiency, should also be associated with hypertriglyceridemia. Several conceivable mechanisms for hypertriglyceridemia could be proposed. Low levels of bile acids might downregulate farnesoid X receptor–responsive gene products, including apoC-II, an activator of lipoprotein lipase, the enzyme that removes triglycerides from the plasma (9). Alternatively, it is possible that elevated oxysterol levels in the liver might induce liver X receptor–responsive genes, leading to increased SREBP-1C expression and increased triglyceride synthesis (10, 11). Consistent with the latter model, Pullinger and colleagues (3) found higher levels of an oxysterol-producing enzyme (sterol-27 hydroxylase) in a liver biopsy from one of their homozygotes. However, it is not clear that elevated levels of the enzyme would necessarily cause higher steady-state levels of oxysterols in hepatocytes, as the oxysterols can be converted rapidly to bile acids via an alternate pathway not involving CYP7A1.

**Qualitative and quantitative effects on bile acids**

Pullinger et al. (3) report a 94% reduction in bile acids excretion in one of their homozygotes. In a healthy person, cholic acid synthesis exceeds synthesis of chenodeoxycholic acid by a factor of two. In their patient, fecal bile acid analysis showed that the major bile acid formed was chenodeoxycholic acid. The fact that CYP7A1 deficiency did not abolish bile acid formation is not surprising, since there are several pathways, differing in their initial steps, for conversion of cholesterol into bile acids (Figure 1) (12, 13). The classical neutral pathway involves CYP7A1, which directly converts cholesterol into 7α-hydroxycholesterol (Figure 1a). In the alternate acidic pathway, cholesterol is first converted by sterol hydroxylases into oxysterols, the major one being 27-hydroxycholesterol. These oxysterols then undergo 7α-hydroxylation by an oxysterol 7α-hydroxylase, either CYP7B1 or CYP39A1 (Figure 1b). Subsequent enzymatic steps lead to the preferential conversion of 7α-hydroxycholesterol into cholic acid and the preferential conversion of 7α-hydroxy-oxysterols into chenodeoxycholic acid.

The shift in primary bile acid synthesis toward chenodeoxycholic acid is entirely consistent with decreased CYP7A1 activity and compensation by the acidic pathway. Of note, a low bile acid synthetic rate and preferential formation of chenodeoxycholic acid were observed previously in two hypercholesterolemic patients whose bile acid synthesis profile was characterized by Einarsen et al. (14) a quarter century ago. We wonder whether those patients might have had CYP7A1 mutations.

The 94% reduction in fecal bile acid excretion (equivalent at steady state to hepatic bile acid synthesis) was observed in a single 24-hour stool collection in a single subject. A longer stool collection would seem essential for quantifying accurately the decreased rate of bile acid synthesis. Future studies should be directed at clarifying this issue as well as determining the rate of bile acid secretion, which can be measured by duodenal intubation and isotopic tracer studies. Better characterization of bile acid biosynthesis in human CYP7A1-deficient patients is particularly important given a distinct lack of evidence for cholesterol or vitamin malabsorption in those individuals. Given that adequate intraluminal concentrations of bile acids are essential for the absorption of cholesterol and fat-soluble vitamins, it seems possible that increased intestinal reclamation of bile acids in CYP7A1-deficient patients may have compensated for their decrease in bile acid biosynthesis. In the guinea pig, low concentrations of bile acids within the lumen of the intestine upregulate the ileal bile acid transport system (15).

**Differences in CYP7A1-deficient mice and humans**

The normal cholesterol absorption and normal vitamin E levels in humans with CYP7A1 deficiency contrasts with findings in Cyp7a1-deficient mice, where the bile acid pool size is reduced by 80%. In those mice, cholesterol absorption was almost abolished (16), and tissue vitamin E levels are markedly reduced (17). Pullinger et al. (3) also found triglyceride malabsorption in one of the homozygotes—a very unexpected finding given that triglyceride absorption is normal in the Cyp7a1-deficient mice (16).

A single liver biopsy in one subject suggested that liver cholesterol levels might be increased in CYP7A1-deficient humans. That observation, although in accordance with the authors’ hypothesis, would not have been predicted from animal models (16). In chow-fed Cyp7a1-deficient mice, liver cholesterol levels are not increased, and cholesterol synthesis rates actually increase, likely secondary to reduced absorption of cholesterol in the intestine (16). When additional humans with CYP7A1 deficiency are identified— if liver biopsies are possible—it will be very interesting to determine if elevated liver cholesterol levels are a consistent feature of CYP7A1 deficiency. It will also be desirable to examine the expression level of the LDL receptor and other gene products regulated by SREBPs.

Additional mysteries are apparent when one compares Cyp7a1-deficient mice and the CYP7A1-deficient humans. The humans were hyperlipidemic, but the mice were not (17), at least when originally characterized (although see refs. 18–20 for evidence of hypercholesterolemia in some genetic backgrounds). Also, in the case of the mice, Cyp7a1 deficiency abolished cho-
lesterol 7α-hydroxylase activity in the liver, but in the humans, the liver biopsy study suggested that cholesterol 7α-hydroxylase activity was reduced by only ~70%. This difference raises the possibility that some other enzyme, perhaps an oxysterol 7α-hydroxylase, can hydroxylate the C-7 position of cholesterol in humans. Finally, increased sterol-27 hydroxylase levels in a liver biopsy from one of the CYP7A1 deficient patients suggest that the oxysterol pathway is upregulated in humans, a response that was not observed in Cyp7a1-deficient mice (13).

Cyp7a1 expression is critical for mice in the postnatal period because Cyp7b1 expression is not turned on until 3 weeks of age. Most Cyp7a1-deficient mice die before weaning unless they are supplemented with cholic acid and fat-soluble vitamins (21). In contrast, as noted above, there was no indication that the CYP7A1-deficient patients had significant fat malabsorption or fat-soluble vitamin deficiencies as children. Thus, the activity of alternate bile acid synthesis pathways together with intestinal conservation of bile acids was apparently sufficient to prevent overt lipid malabsorption.

Humans and mice also exhibit different phenotypes for mutations in other bile acid metabolism–related proteins. A human infant lacking CYP7B1, who died with severe biliary cholestasis, has been described (22). In contrast, Cyp7b1-deficient mice appear perfectly healthy (23). Mice deficient in the canalicular bile salt export pump have mild cholestasis (24), whereas humans with this defect develop progressive familial cholestasis, a merciless pediatric disease causing early cirrhosis (25). Loss of sterol 27-hydroxylase in humans causes a striking deficiency of bile acids, cerebrotendinous xanthomatisosis, and an accumulation of cholesterol in tissues (26–28). Mice with the same enzyme defect have a bile acid synthesis defect but do not develop cerebrotendinous xanthomatisosis. Instead, they manifest elevated triglyceride levels in liver and plasma (29). Thus, when it comes to disorders of bile acid and cholesterol metabolism, clinical investigators would be wise to study both mice and humans.